Are psychostimulant medications contraindicated during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Psychostimulants Are NOT Contraindicated in Pregnancy

Psychostimulants should not be stopped during pregnancy if they are required for daily functioning, as the documented risks are very low and treatment discontinuation can lead to worse maternal outcomes that may harm both mother and fetus. 1

Key Evidence-Based Recommendations

The most recent 2024 American Journal of Obstetrics and Gynecology guidelines provide clear direction on this question 1:

Core Principle

The consensus is that the magnitude of documented risks is very low and treatment with medications should not be stopped if they are required for the daily functioning of the pregnant person. 1

Risk Assessment

While some evidence suggests psychostimulants might increase risks for:

  • Preeclampsia
  • Preterm birth
  • Low birth weight
  • Poor neonatal adaptation

The magnitude of these documented risks is arguably not clinically meaningful, and evidence suggests these risks may be elevated in ADHD itself rather than being directly attributable to the medication. 1

Specific Medication Safety Data

Methylphenidate:

  • Does not appear associated with major congenital malformations 1
  • Most thoroughly investigated ADHD medication 2
  • For new users, appears to be the "safest" choice 2

Amphetamines:

  • Do not appear associated with major congenital malformations or cardiac malformations 1
  • Possible small increased risk for preeclampsia (aRR 1.29,95% CI 1.11-1.49), but other studies have not found this association 1
  • Possible small increased risk for preterm birth when continued in second half of pregnancy (aRR 1.30,95% CI 1.10-1.55) 1
  • For patients already doing well on amphetamines, there is no compelling reason to switch medications based on safety concerns 2

Clinical Management Algorithm

Preconception Phase

  1. If medication is not likely to severely impact daily functioning: Consider trial of gradual discontinuation 1
  2. If unable to discontinue:
    • Continue current medication OR
    • Reduce to lowest effective dose OR
    • Consider intermittent use OR
    • Consider switching to nonstimulant option
  3. Always engage in risk-benefit discussion 1

During Pregnancy

  1. Continue psychostimulant with risk-benefit discussion regarding:
    • Continuing current well-tolerated, effective dose
    • Considering intermittent use (to maximize functioning while reducing fetal exposure) 1
  2. Monitor pregnancy carefully:
    • Fetal growth assessments
    • Blood pressure checks
    • Ensure appropriate maternal weight gain 1

Alternative Considerations

  • Bupropion can be considered as alternative, particularly with co-occurring depression, given available perinatal safety data 1
  • Important caveat: Bupropion is not as efficacious as stimulants for ADHD treatment 1

Critical Nuances

Confounding by Indication

The 2025 meta-analysis found that in utero exposure to methylphenidate, amphetamines, and atomoxetine does not increase risk of neurodevelopmental disorders in offspring 2. This study specifically addressed confounding by indication through sibling comparisons and found associations were attenuated after adjustment.

Quality of Existing Evidence

Much existing evidence showing risks comes from:

  • Small studies examining illicit stimulant use 1
  • Studies of multiple medications in combination 1
  • Several other studies found no adverse effects 1

Risks of Untreated ADHD

Discontinuing psychostimulant treatment during pregnancy can lead to:

  • Worse mental health outcomes 1
  • Significant impairments in maternal functioning 1
  • Negative impacts on developing fetus/baby 1
  • Untreated ADHD itself is associated with increased risks for spontaneous abortion and preterm birth 1

Common Pitfalls to Avoid

  1. Do not automatically discontinue stimulants upon pregnancy diagnosis - this is a common but outdated practice 1
  2. Do not assume all pregnancy complications are medication-related - ADHD itself carries risks 1
  3. Do not switch medications unnecessarily - if patient is stable on amphetamines or atomoxetine, continuation is reasonable 2
  4. Do not ignore maternal quality of life - functional impairment from untreated ADHD has real consequences 1

Breastfeeding Considerations

  • Methylphenidate: Maintain therapeutic dose - secreted in minimal amounts (RID <1%), generally not detected in infant blood, no adverse effects reported 1
  • Amphetamines: Discuss breastfeeding safety, consider intermittent use and timing of feeding 1

References

1
Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Related Questions

What are the safest antipsychotic and antidepressant options for a pregnant woman in her first trimester?
In a patient with early pregnancy (quantitative serum hCG 527 IU/L) who is taking risperidone 1 mg twice daily, bupropion sustained‑release 100 mg daily, dextroamphetamine‑amphetamine extended‑release 10 mg daily, and melatonin 3 mg nightly (6 mg as needed), what medication changes are recommended to ensure safety for the fetus while maintaining psychiatric stability?
Is it safe to use Adderall (mixed amphetamine salts) and risperidone during pregnancy?
What psychiatric sleep medications are considered safe for use during pregnancy?
Are buspirone, pantoprazole, quetiapine, sertraline, and trazodone safe to use during pregnancy?
How should a comprehensive evaluation of maternal mortality be performed in Brazil for the states of [state] and [state], covering definition, prevention, detection, intervention, direct and indirect causes, variable relationships, investigation forms (maternal death and home investigation), necropsy reports, determinants of avoidable vs unavoidable deaths, system fragilities, and quality‑improvement indicators?
Should a 79-year-old woman with severe iron‑deficiency anemia (hemoglobin 6.5 g/dL) receive a red blood cell transfusion, and what steps should be taken now that she missed her gastroenterology appointment?
For a 60‑year‑old patient with several months of non‑restorative sleep, leg discomfort and urge to move the legs at night, and episodic involuntary leg movements during sleep, which medication—sertraline, melatonin, duloxetine, or gabapentin—is the most appropriate treatment?
For a 48-year-old man with hypertension, obesity (BMI 30), and chronic ibuprofen use for bilateral knee pain, should I start a glucagon-like peptide‑1 receptor agonist, initiate a thiazide‑type diuretic, or continue ibuprofen?
What is the recommended antibiotic regimen and management for a 53-year-old female with a labia majora abscess caused by Staphylococcus aureus who is currently taking doxycycline?
What is the most likely cause and recommended management for new balance disturbances and blurred vision in a patient with a tapeworm infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.